Cargando…

Long COVID in Inflammatory Bowel Diseases

Background and aims. SARS-CoV-2-infected patients can experience long-lasting symptoms even after the resolution of the acute infection. This condition, defined as Long COVID, is now recognized as a public health priority and its negative impact on the quality of life of the patients could be more r...

Descripción completa

Detalles Bibliográficos
Autores principales: Salvatori, Silvia, Baldassarre, Francesco, Mossa, Michelangela, Monteleone, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8658587/
https://www.ncbi.nlm.nih.gov/pubmed/34884276
http://dx.doi.org/10.3390/jcm10235575
_version_ 1784612765076291584
author Salvatori, Silvia
Baldassarre, Francesco
Mossa, Michelangela
Monteleone, Giovanni
author_facet Salvatori, Silvia
Baldassarre, Francesco
Mossa, Michelangela
Monteleone, Giovanni
author_sort Salvatori, Silvia
collection PubMed
description Background and aims. SARS-CoV-2-infected patients can experience long-lasting symptoms even after the resolution of the acute infection. This condition, defined as Long COVID, is now recognized as a public health priority and its negative impact on the quality of life of the patients could be more relevant in individuals with debilitating pathologies. We here evaluated the frequency of Long COVID in patients with inflammatory bowel diseases (IBD). Methods. IBD patients afferent for scheduled visits to our tertiary referral center at the Tor Vergata University Hospital, Rome, were recruited from 7 September to 22 October 2021. During the visits, patients were investigated about previous COVID-19 infection and the possible development of Long COVID. Results. Fifty-three out of 528 IBD patients (10%) have had a SARS-CoV-2 infection. Of these, 21 patients (40%) developed Long COVID, and asthenia was the more frequent symptom as it occurred in nearly two-thirds of patients. Patients with Long COVID were more frequently females, while other clinical and demographic characteristics did not differ between patients with Long COVID and those without Long COVID. In particular, the IBD relapses occurred with the same frequency in the two groups. Conclusions. Long COVID appears to be common in IBD patients even though it does not influence the IBD course.
format Online
Article
Text
id pubmed-8658587
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86585872021-12-10 Long COVID in Inflammatory Bowel Diseases Salvatori, Silvia Baldassarre, Francesco Mossa, Michelangela Monteleone, Giovanni J Clin Med Communication Background and aims. SARS-CoV-2-infected patients can experience long-lasting symptoms even after the resolution of the acute infection. This condition, defined as Long COVID, is now recognized as a public health priority and its negative impact on the quality of life of the patients could be more relevant in individuals with debilitating pathologies. We here evaluated the frequency of Long COVID in patients with inflammatory bowel diseases (IBD). Methods. IBD patients afferent for scheduled visits to our tertiary referral center at the Tor Vergata University Hospital, Rome, were recruited from 7 September to 22 October 2021. During the visits, patients were investigated about previous COVID-19 infection and the possible development of Long COVID. Results. Fifty-three out of 528 IBD patients (10%) have had a SARS-CoV-2 infection. Of these, 21 patients (40%) developed Long COVID, and asthenia was the more frequent symptom as it occurred in nearly two-thirds of patients. Patients with Long COVID were more frequently females, while other clinical and demographic characteristics did not differ between patients with Long COVID and those without Long COVID. In particular, the IBD relapses occurred with the same frequency in the two groups. Conclusions. Long COVID appears to be common in IBD patients even though it does not influence the IBD course. MDPI 2021-11-26 /pmc/articles/PMC8658587/ /pubmed/34884276 http://dx.doi.org/10.3390/jcm10235575 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Salvatori, Silvia
Baldassarre, Francesco
Mossa, Michelangela
Monteleone, Giovanni
Long COVID in Inflammatory Bowel Diseases
title Long COVID in Inflammatory Bowel Diseases
title_full Long COVID in Inflammatory Bowel Diseases
title_fullStr Long COVID in Inflammatory Bowel Diseases
title_full_unstemmed Long COVID in Inflammatory Bowel Diseases
title_short Long COVID in Inflammatory Bowel Diseases
title_sort long covid in inflammatory bowel diseases
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8658587/
https://www.ncbi.nlm.nih.gov/pubmed/34884276
http://dx.doi.org/10.3390/jcm10235575
work_keys_str_mv AT salvatorisilvia longcovidininflammatoryboweldiseases
AT baldassarrefrancesco longcovidininflammatoryboweldiseases
AT mossamichelangela longcovidininflammatoryboweldiseases
AT monteleonegiovanni longcovidininflammatoryboweldiseases